Skip to content
value.today

Azitra, Inc.

AZTR
$5 Mmarket cap on Oct 30, 2026
1M
+347.6%
Compare
World rank
#27,017
Revenue
—
For year ending December-2025
Net income
$-11 M
SEC filing
Employees
13
As of December 31, 2025
SEC filing

Azitra, Inc. in brief

Azitra, Inc. is a listed company in the Biotechnology industry, based in Branford, Connecticut, USA. Its market value was $5 M on 30 October 2026, which makes it the 27,017th largest listed company in the world and the 4,417th largest in the USA on this site. It employs about 13 people. Its shares trade under the symbol AZTR (NYSE).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Azitra, Inc.

Azitra, Inc. was formed as a Delaware corporation on January 2, 2014 as a biopharmaceutical company focused on developing innovative therapies for precision dermatology using engineered proteins and topical live biotherapeutic products. Since our formation, we have built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for unique therapeutic characteristics. The platform is augmented by an artificial intelligence and machine learning technology that analyzes, predicts and helps screen our library of strains for drug like molecules. The platform also utilizes a licensed genetic engineering technology, which can enable the transformation of previously genetically intractable strains. We have not commenced commercial operations. Unless otherwise indicated, the terms “Azitra,” Company,” “we,” “us,” and “our” refer to Azitra, Inc. and its wholly-owned subsidiaries.

From the company's annual report filed with the US SEC: read the report

Azitra, Inc. timeline

2 events, 2017–2023
  1. 2017
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2023
  4. 💰
    Record revenue of $1 million
    FY2023, the highest of the 3 years on record.

Events of Azitra, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$1 M$2 M$4 M$5 M

World rank over time

▲ up 920 places since 2026
2026-09-23: #27943#27,94320262026-10-30: #27023#27,0232026

Rank in USA: #4,446 (Sep 2026) · #4,418 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
1.2×
Free cash flow yield
-243.8%
Net margin
—
Operating margin
—
Return on equity
-288.4%
Liabilities / assets
24.3%
Revenue growth
-98.6%
R&D / revenue
47200.0%
Profit per employee
$-843 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2022: revenue $0M, net income $-11M$0MFY22Fiscal year ending Dec 2023: revenue $1M, net income $-11M$1MFY23Fiscal year ending Dec 2024: revenue $0M, net income $-9M$0MFY24Fiscal year ending Dec 2025: revenue —, net income $-11M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-11M$-11M—
Dec 2024$0M-98.6%$-11M$-9M-89700.0%
Dec 2023$1M+146.4%$-7M$-11M-1634.8%
Dec 2022$0M—$-9M$-11M-3814.3%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-11M$0M$-11M$-2.25—
Dec 2024$-10M$0M$-10M$-15.70—
Dec 2023$-7M$0M$-7M$-54.98—
Dec 2022$-8M$0M$-8M$-12.74—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-2M—Dec ’24Three months to Mar 2025: revenue —, net income $-3M—Mar ’25Three months to Jun 2025: revenue —, net income $-3M—Jun ’25Three months to Sep 2025: revenue —, net income $-3M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-2M—Dec ’25Three months to Mar 2026: revenue —, net income $-4M—Mar ’26Three months to Jun 2026: revenue —, net income $-3M—Jun ’26Three months to Sep 2026: revenue —, net income $-3M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-3M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Azitra, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-11 M
Net income
$-11 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$5 M
Total liabilities
$1 M
Total equity
$4 M

As of December-2025

Top 20 institutional investors in Azitra, Inc.#

As of Sep 30, 2026
20 institutions held 21.4 M shares on Sep 30, 2026. Source: SEC Form 13F filings, filed through Nov 18, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 20 largest institutional investors in Azitra, Inc.
#InstitutionShares heldChange (shares)ValueFiled
1Dauntless Investment Group, LLC12,553,737+1,261,551 (+11.17%)$2 MNov 16, 2026
2Stonepine Capital Management, LLC5,227,438-58,038 (-1.10%)$1 MNov 13, 2026
3Nantahala Capital Management, LLC2,213,613-2,213,613 (-50.00%)$0 MNov 13, 2026
4Vanguard Fiduciary Trust Co322,116New$0 MNov 13, 2026
5Susquehanna International Group, LLP238,246+226,009 (+1846.93%)$0 MNov 16, 2026
6Jane Street Group, LLC222,375-26,058 (-10.49%)$0 MNov 12, 2026
7HRT Financial LP161,002New$0 MNov 13, 2026
8Geode Capital Management, LLC95,4090 (0.00%)$0 MNov 6, 2026
9StoneX Group Inc.84,671+56,020 (+195.53%)$0 MNov 3, 2026
10Virtu Financial LLC67,259+2,319 (+3.57%)$0 MNov 17, 2026
11Tower Research Capital LLC (TRC)52,604+33,104 (+169.76%)$0 MNov 16, 2026
12UBS Group AG37,855-12,626 (-25.01%)$0 MNov 10, 2026
13Two Sigma Securities, LLC21,916New$0 MNov 16, 2026
14Flow Traders U.S. LLC21,750New$0 MNov 13, 2026
15Corient Private Wealth LP14,4510 (0.00%)$0 MNov 16, 2026
16XTX Topco Ltd14,064New$0 MNov 16, 2026
17Citigroup Inc2,526-3,623 (-58.92%)$0 MNov 4, 2026
18Robinhood Markets, Inc.639—$0 MNov 18, 2026
19Strategic Financial Concepts, LLC197New$0 MNov 16, 2026
20Barclays PLC7+6 (+600.00%)$0 MNov 6, 2026

Mutual funds holding Azitra, Inc.#

1 funds hold shares worth $0 M (about 5.9% of the company). Since their previous reports 1 added shares and 1 sold, buying $0 M net.
Mutual funds holding Azitra, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC359,022$0 M5.9%<0.01%+384%May 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of May 31, 2026. The 1 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Azitra, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
7
since
$105 K$0Feb 2024: bought $105 K (3 trades), sold $0 (0 trades)Feb 24Mar 2024: bought $10 K (1 trades), sold $0 (0 trades)Mar
Bought (open market)Sold (open market)Hover a month for the totals
Azitra, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Francisco D. SalvaPresident and CEO, DirectorConversion+4.06 M——4.09 MForm 4
filed Norm StaskeyChief Financial OfficerBuy+47,600$0.210$10 K51,100Form 4
filed Travis WhitfillChief Operating Officer, DirectorBuy+15,000$0.300$5 K334,500Form 4
filed Norm StaskeyChief Financial OfficerBuy+3,300$0.300$9903,500Form 4
filed Francisco D. SalvaPresident and CEO, DirectorBuy+333,300$0.300$100 K338,300Form 4
filed Bayer World Investments B.V.10% ownerConversion+1.31 M——1.31 MForm 4
filed Andrew McClaryDirectorConversionindirect · amended+249,474——249,474Form 4/A
filed Andrew McClaryDirectorConversionindirect · amended+42,437——291,911Form 4/A

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Azitra, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
305,802
28.5% of shares · 1 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-6.66 reverse split ; 1-for-30.03 reverse split ; 7.1-for-1 split

Trading halts

  • 2026-10-26 18:37 UTC, code M, resumed 18:42 UTC
  • 2026-10-26 18:31 UTC, code M, resumed 18:36 UTC
  • 2026-10-26 17:25 UTC, code M, resumed 17:30 UTC
  • 2026-10-26 17:10 UTC, code M, resumed 17:15 UTC
  • 2026-10-26 16:49 UTC, code M, resumed 16:54 UTC

Fails to deliver

  • : 3,427 shares at $0.76
  • : 51,386 shares at $1.12
  • : 538,155 shares at $1.53
  • : 111 shares at $0.17
  • : 1,349 shares at $0.17

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Azitra, Inc. scorecard#

Passes 2 of the 8 checks that could be worked out. Fiscal year 2025; market cap of Oct 30, 2026.

  • Valuation1 of 3
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median1.2×Price to book 1.2× against Biotechnology's median of 2.9×.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • –Free cash flow yield above 5%No free cash flow yield on file.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 1
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-2.25 vs -15.70Diluted EPS -2.25 in fiscal 2025 against -15.70 the year before (report's currency).
    • –Net income higher than five years earlierNet income of five years earlier is not on file.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 2
    • ✗Profitable in the newest year-$11 MNet income -$11 M in fiscal 2025.
    • –Profitable in each of the last five yearsFive years of net income are not on file.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-230.7%-230.7% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities2.8×Current ratio 2.82 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returnsnot known
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Azitra, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Azitra, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022
Income statement
Revenue07.5686284
Research and development4,8364,7233,643r6,098
General and administrative6,1316,2694,4933,640
Operating expenses10,96710,9938,137r9,738
Operating income−10,967−10,985−7,451r−9,454
Interest expense and finance costs7.612168252
Other non-operating income (expense)202,027−3,816r−1,227
Income before tax−10,947−8,958−11,266−10,680
Income tax8.39.017—
Net income attributable to shareholders−10,955−8,967−11,284−10,680
Earnings per share, basic-2.25-15.70r-54.98r-12.74
Earnings per share, diluted-2.25-15.70r-54.98r-12.74
Shares, weighted average (basic)4.90.6r0.2r1.1
Shares, weighted average (diluted)4.90.6r0.2r1.1
Balance sheet
Cash and cash equivalents2,0684,5551,7963,493
Receivables0.90.2—175r
Current assets3,0195,2282,5364,136
Property, plant and equipment549654710847
Right-of-use (leased) assets4045278291,117
Other intangible assets317246211220
Total assets5,0257,3595,1157,167
Accounts payable399490897785
Current liabilities1,0681,3761,6032,222
Lease liabilities (non-current)156274538841
Total liabilities1,2241,6612,2029,733
Retained earnings−68,521−57,566−48,597r−37,315
Shareholders' equity3,8015,6982,913−36,260
Total liabilities and equity5,0257,3595,1157,167
Shares outstanding1.1r1.1r0.4r1.0
Cash-flow statement
Depreciation and amortization138131130126
Share-based compensation63245152184
Cash from operating activities−11,224−10,184−7,362−8,349
Capital expenditure−24−8.6−27−33
Cash from investing activities−183−379−318−337
Shares issued5,9420——
Cash from financing activities8,92013,3225,9844,135
Report10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Events at Azitra, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling
  • Delisting noticeFiling
  • Delisting noticeFiling

Delisting notice 3 · Material agreement 4 · Unregistered share sale 2 · Shareholder rights changed 2 · Bylaws or fiscal year changed 4 · Shareholder vote 1 · Results announced 6

Azitra, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Shareholder rights changedBylaws or fiscal year changed8-K
Material agreement8-K
Results announced8-K
Bylaws or fiscal year changedShareholder vote8-K
Results announced8-K
Material agreementUnregistered share saleBylaws or fiscal year changed8-K
Delisting notice8-K
Results announced8-K
Delisting notice8-K
Material agreementUnregistered share sale8-K
Results announced8-K
Delisting notice8-K
Material agreement8-K
Shareholder rights changedBylaws or fiscal year changed8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026

Acquisitions and funding#

5 private funding rounds before listing

Private share sales · funding history

Private share sales of Azitra, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jan 2021$1 MNo. 5Under $2 million1equity, debt, optionsSEC
Sep 2020$17 MNo. 4$10 to $50 million8equitySEC
Feb 2019$5 MNo. 3$2 to $10 million5equity, optionsSEC
Apr 2018$2 MNo. 2$2 to $10 million5debt, optionsSEC
Mar 2017$3 MNo. 1$2 to $10 million3equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

How Azitra, Inc. compares in Biotechnology

  • Market cap$5 M · higher than 5% of 726
  • Revenue growth-98.5% · higher than 1% of 438
  • Price / book1.2× · lower than 75% of 534

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Azitra, Inc.🇺🇸$5 M——-98.5%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 30, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Azitra, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Azitra, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Azitra, Inc.? Suggest a correction